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HCV 
Magnitude of the problem 
 
• 170 million people world wide affected by HCV 
 
• About 1 to 2 % of the population in  industrial 
countries is infected with HCV. 
 
• Number one cause of liver failure requiring liver 
transplant 
 
 
The global burden of hepatitis C 
Liver International 2009; 29(s1): 74–81 
Natural history of HCV infection 
 
• 20% of acutely infected patients spontaneously 
clear the virus 
• 75% to 85% progress to chronic infection 
•  Rate of chronic infection varies by age, sex, race, 
and immune system status 
• 20% of chronically infected individuals will 
develop cirrhosis over a 20- to 25-year period 
• 3%–4% will develop HCC per year 



Characteristics of adult liver transplant recipients,  
SRTR 2009 



Decompensated Cirrhosis 
• Portal Hypertension 
− Esophageal variceal bleeding 
− Ascites 
• SBP 
• Encephalopathy 
• Hepatorenal Syndrome 
• Hepatopulmonary Syndrome 
• Portopulmonary Hypertension 
• Coagulopathy 
• Jaundice 
• Pruritus 
• Sleep wake cycle disturbances 
 
 
Liver Transplant 
• Allocation of Organ based on MELD 
• Predictor of 3 month wait list mortality 
 

HCV 
Post Transplant Course 
• Graft reinfection with HCV is universal  
• Fibrosis progression is accelerated , compared to 
immunocompetent patients . 
•  Patients have a 23% increased rate of mortality and a 30% 
increased rate of graft loss at 5 years post-transplantation as 
compared to patients transplanted for other indications  
• Cirrhosis is reported in up to 30% of recipients within 5 years 
•  Once cirrhosis is established, patients are at high risk for 
complications, with up to 42% developing liver decompensation 
within 1 year  
• Retransplantation, is controversial in patients with HCV, as their 
survival is inferior compared to patients with non-HCV indications 
Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C 
infection and survival after orthotopic liver transplantation. 
Gastroenterology. 
2002;122:889–896. 
• Retrospective cohort study of 11,036 patients (4439 HCV-positive and 6597 
HCV-negative). 
 
•  Patients transplanted for HCV-related cirrhosis had an increased rate of death 
and allograft failure compared with patients transplanted for causes other than 
HCV. 
• There was a 23% increased mortality rate and 30% increased allograft failure 
rate associated with HCV infection. 
 


Factors negatively affecting post transplant 
outcome 
• Clinically significant histological recurrence 
within the first year of transplantation 
• Advanced fibrosis stage at the 1 year protocol 
liver biopsy (fibrosis stage  2) 
• Acute cellular rejection within the first 3 months 
of LT  
• Donor age  
• History of pretransplant HCC (regardless of prior 
therapy) 
 
Potential antiviral strategies for treatment of recurrent hepatitis C. Courtesy of Dr. Ed Gane. 
Snydman D R et al. Clin Infect Dis. 2003;37:807-812 
© 2003 by the Infectious Diseases Society of America 
When to treat HEP C 
Pre transplant  
Martinez-Bauer E, Carrion JA, Ramirez S, et al. Antiviral therapy of 
patients with decompensated cirrhosis to prevent hepatitis C 
recurrence after liver transplantation. J Hepatol 2006;44: 
S64.A150. 
 
• 50 cirrhotic patients with HCV on the LT waiting list. 
• The baseline model for end-stage liver disease (MELD) score was 12 
• pegylated interferon and ribavirin  
Martinez-Bauer E, Carrion JA, Ramirez S, et al. Antiviral therapy of 
patients with decompensated cirrhosis to prevent hepatitis C 
recurrence after liver transplantation. J Hepatol 2006;44: 
S64.A150 
• 46% of patients became HCV-RNA negative before transplantation 
− Post-LT SVR of 71%  
− Relapse rate of 29%. 
− 20% of genotype 1 patients maintained post-LT SVR.  
• Side effects included  
− Life-threatening complications : 
− Hepatic decompensation and infection (32%) 
−  Neutropenia (20%) 
−  2 deaths on therapy (spontaneous bacterial peritonitis) 
 
Immunosupression 
 
Cyclosporin VS Tacrolimus 
Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis 
C virus in vitro and increases the chance of a sustained 
virological response after liver transplantation. Liver Transpl 
2006;12:51–57. 
•  Patients treated with cyclosporine  
• 46% were more likely to achieve SVR vs patients treated with tacrolimus (27%) 
•  There was no statistically significant difference in patient survival between the 
2 groups 
•  cyclosporine treated patients had a lower baseline HCV RNA  
• More episodes of acute cellular rejection requiring steroid treatment. 
O’Grady JG, Hardy P, Burroughs AK, et al. UK and Ireland Liver 
Transplant Study Group. Randomized controlled trial of tacrolimus 
versus microemulsified cyclosporin (TMC) in liver transplantation: 
post-study surveillance to 3 years. Am J Transplant 2007; 
7:137–141. 
  
 
• No difference in outcomes in cyclosporine- vs tacrolimus-treated HCV patients 
at 3 years 
Risks and Benefits of Antiviral Therapy for Recurrent 
HCV 
Benefits 
 
 
• Only medications shown to eradicate recurrent 
HCV 
• Virus eradication would substantially improve 
outcome 
Risks 
• Frequently ineffective in genotype 1  
• Optimal time for treatment initiation unclear 
• Duration of treatment for fibrosing cholestatic HCV 
unknown 
• Numerous side effects that can be serious and often lead 
to treatment discontinuation 
• Expensive 
• Progressive fibrosis with decompensation reported 
despite SVR 

UMASS MEMORIAL MEDICAL CENTER 
• 1998 To Present 
• 350 consecutive Liver Transplants 
• 158 cases of HCV + Recipients (45%) 
• 192 cases of HCV – Recipients  (55 %) 
Hcv – 
N = 192 
HCV+ 
N = 158 
P 
Age 56 54 0.6 
MELD 18.9 18.7 0.4 
Male 107 124 NS 
Female 85 34 0.000 
White 151 110 NS 
AA 4 5 NS 
Other 37 43 NS 
Import 59 33 0.01 
Donor Age 55.5 48.5 0.000 
DRI 2.12 1.81 0.001 
 Chi-Square df Sig.
Log Rank (Mantel-
Cox)         
9.932 1 .002
Breslow 
(Generalized 
Wilcoxon)
10.062 1 .002
Tarone-Ware                   11.030 1 .001
Overall Comparisons
N Percent
No 191 43 148 .8
Yes 158 59 99 .6
Overall 349 102 247 .7
Case Processing Summary
Recipient 
HCV Total N N of Events
Censored
158 HCV + recipients  
Treatment (--) 
N=72 
Treatment (+) 
N=86 
P 
Age 54 54 NS 
MELD 19.6 17.75 0.49 
Female 19 15 NS 
Male 53 71 NS 
White 50 60 NS 
AA 2 3 NS 
Other 20 23 NS 
Import 15 18 0.99 
Donor Age 52 45 0.36 
Donor sex (F) 15 23 NS 
Donor sex (M) 34 36 NS 
DRI 1.86 1.74 0.95 
UMass HCV+ Patients Treated vs. Non-Treated 
 Chi-Square df Sig.
Log Rank 
(Mantel-Cox)         
3.993 1 .046
Breslow 
(Generalized 
Wilcoxon)
5.223 1 .022
Tarone-Ware                   4.969 1 .026
Overall Comparisons
N Percent
None 72 32 40 .6
Treated 86 27 59 .7
Overall 158 59 99 .6
Case Processing Summary
HCV any 
Treatment Total N N of Events
Censored
UMass HCV+ Patients Treated vs. Non-Treated 
 Chi-Square df Sig.
Log Rank 
(Mantel-Cox)         
7.157 2 .028
Breslow 
(Generalized 
Wilcoxon)
5.340 2 .069
Tarone-Ware                   5.976 2 .050
Overall Comparisons
N Percent
Treatment 
Prior to Tx
51 18 33 .6
Treatment 
Post Tx
22 8 14 .6
Treatment 
Prior to Tx 
and Post Tx
13 1 12 .9
Overall 86 27 59 .7
Case Processing Summary
HCV 
Treatment Total N N of Events
Censored
UMass HCV+ Patients SVR vs. Non-SVR 
 Chi-Square df Sig.
Log Rank 
(Mantel-Cox)         
1.406 1 .236
Breslow 
(Generalized 
Wilcoxon)
1.238 1 .266
Tarone-Ware                   1.325 1 .250
Overall Comparisons
N Percent
No 78 26 52 .7
Yes 8 1 7 .9
Overall 86 27 59 .7
Case Processing Summary
SVR Total N
N of 
Events
Censored
